Posts by: Leonor Mateus Ferreira

Leonor Mateus Ferreira

Leonor is an emerging, young journalist who writes daily for BioNews Texas, covering business, science, and health news. She holds a bachelor’s degree in Communication and post-graduate degree in Multiplatform Journalism. She is particularly interested in politics and current affairs, and is currently studying for a masters degree in economics and public policies.

January 5, 2015January 5, 2015

PCORI Board Grants $50 Million Funding for Hepatitis C Clinical Effectiveness Research

Hepatitis C, News

The Patient-Centered Outcomes Research Institute (PCORI) has granted $50 million for the development of four comparative clinical effectiveness research (CER) studies dedicated to the diagnosis and treatment of hepatitis C virus (HCV) ... Read more

January 2, 2015January 2, 2015

Bristol-Myers Foundation Funds HBV, HCV Projects in China and India

Hepatitis B, Hepatitis C, News

Bristol-Myers Squibb Foundation recently granted nine awards to research projects dedicated to studying and fighting hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in China and India. The foundation has ... Read more

December 30, 2014December 30, 2014

Walter & Eliza Hall is Enrolling Patients for Hepatitis B Treatment Phase I/IIa Trials

News

The Walter and Eliza Hall Institute is studying a potential treatment to cure chronic hepatitis B virus (HBV) infections, and is currently recruiting 50 patients to enroll in the Phase I and ... Read more

December 17, 2014December 17, 2014

Cartoons Help Improve Knowledge on Hepatitis B Serology

Hepatitis B, News

The use of cartoons to explain hepatitis B serology may aid in the improvement of interpretation knowledge and disease understanding, according to the results of a study led by Australian ... Read more

December 11, 2014December 20, 2014

Simeprevir as Effective as Standard Hepatitis C Therapy with Telaprevir

Hepatitis C, News

Treating patients who suffer from chronic Hepatitis C virus infection (HCV) with once a day protease inhibitor simeprevir along with interferon and ribavirin has been demonstrated to be as effective as administering them with telaprevir with ... Read more

November 20, 2014November 20, 2014

OnCore and Baruch S. Blumberg Institute Partner Up to Cure Hepatitis B

Hepatitis B, News

OnCore Biopharma, Inc., a company focused on the development and commercialization of oral medication for the treatment of chronic hepatitis B virus (HBV) infection, has established a collaboration with the research ... Read more

November 3, 2014November 3, 2014

Swedish County Councils Signs Agreement for Hepatitis C Therapy Olysio

Hepatitis C, News

The Swedish county councils has established a risk-sharing agreement with research-based pharmaceutical company Medivir AB for the medication Olysio (simeprevir) for hepatitis C, including its treatment costs, as a way of making ... Read more

October 31, 2014November 3, 2014

Hepatitis B Disproportionately Affects Uganda, Especially Young and Pregnant Women

Hepatitis B, News

The Hepatitis B virus is widely affecting people who live in the northern region of Uganda, including women who are pregnant and under 20 years old. These are the alarming results of ... Read more

October 30, 2014October 30, 2014

Australia Declines to Subsidize Hepatitis C Drug Therapy Sofosbuvir

Hepatitis C, News

The drug Sofosbuvir, for the treatment of hepatitis C, produced by Gilead Sciences, will not be subsidized by the Australian government, due to its costs. The Pharmaceutical Benefits Advisory Committee (PBAC) announced that ... Read more

October 27, 2014October 27, 2014

Spanish HIV-HCV Patients More Difficult to Treat Than Other Ethnic Groups

Hepatitis C, News

Spanish patients suffering from both HIV and hepatitis C virus (HCV) are more difficult to treat than patients from other ethnic groups, due to their genetics, according to recent research conducted in a ... Read more